Hanwen Su
- Co-authors
- Meixian XiangTianming YangYunjun YanJinyue HuChaoyuan WangChengliang ZhuGuangwen ShuTse Wen Chang
- Topics
- Natural product bioactivities and synthesis (6 papers)COVID-19 Clinical Research Studies (4 papers)SARS-CoV-2 and COVID-19 Research (3 papers)
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Hanwen Su
28 papers receiving 546 citations
Peers
Comparison fields: 5 of 92
- Molecular Biology 173
- Infectious Diseases 119
- Plant Science 100
- Pharmacology 59
- Oncology 53
Countries citing papers authored by Hanwen Su
This map shows the geographic impact of Hanwen Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanwen Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanwen Su more than expected).
Fields of papers citing papers by Hanwen Su
This network shows the impact of papers produced by Hanwen Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanwen Su. The network helps show where Hanwen Su may publish in the future.
Co-authorship network of co-authors of Hanwen Su
This figure shows the co-authorship network connecting the top 25 collaborators of Hanwen Su. A scholar is included among the top collaborators of Hanwen Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanwen Su. Hanwen Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 3 | |
| 4 | 15 | |
| 5 | 2 | |
| 6 | 3 | |
| 7 | 14 | |
| 8 | 0 | |
| 9 | 3 | |
| 10 | 33 | |
| 11 | 17 | |
| 12 | 73 | |
| 13 | 16 | |
| 14 | 7 | |
| 15 | 39 | |
| 16 | 11 | |
| 17 | 1 | |
| 18 | 6 | |
| 19 | 4 | |
| 20 | 27 |
About Hanwen Su
Hanwen Su is a scholar working on Complementary and alternative medicine, Pharmacology and Cancer Research, having authored 30 papers that have together received 567 indexed citations. Recurring topics across this work include Natural product bioactivities and synthesis (6 papers), COVID-19 Clinical Research Studies (4 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). The work is most often cited by research in Infectious Diseases (119 citations), Biochemistry (28 citations) and Animal Science and Zoology (41 citations). Hanwen Su has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Meixian Xiang, Tianming Yang, Yunjun Yan, Jinyue Hu, Chaoyuan Wang, Chengliang Zhu, Guangwen Shu, Tse Wen Chang, Jingtao Huang and Kailang Wu. Their work appears in journals such as Clinical Infectious Diseases, Scientific Reports and Molecules.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.